Strategic Focus OBI USA drives US and European clinical trials for OBI’s novel therapeutics, presenting a need for CRO partnerships, regulatory consultants, and regional distribution collaborators to expedite trial execution and site access.

GlycOBI Platform The GlycOBI glycan site-specific conjugation technology and DUOR dual-drug ADC platform indicate strong opportunities for collaboration with antibody-drug conjugate developers, payload suppliers, and contract development services focused on precision conjugation and multi-function payload linking.

Clinical Showcase Multiple AACR and World ADC Summit activities highlight active R&D and data generation, suggesting demand for translational science partners, biomarker services, and regulatory strategy experts to support trial design and publication preparedness.

Partnership Network Recent MOUs and collaborations with Nippon Fine Chemical and GlyTech signal openness to CDMO and technology licensing partnerships, presenting cross-border sales opportunities for manufacturing, process development, and glycan-related supply chain services.

Funding & Growth Reported revenue in the low millions with a small team suggests partnerships that accelerate scale, including selective outsourcing, clinical operations support, and regional market access services to monetize US and European trial activity efficiently.